Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionPrinceton Global Asset Management LLC
Latest Disclosed Ownership13,263 shares
Latest Disclosed Value $ 5,922,250
Princeton Global Asset Management LLC reports 0.79% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 22, 2026 - Princeton Global Asset Management LLC filed a 13F-HR form disclosing ownership of 13,263 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $5,922,460 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 20, 2026 disclosing 13,159 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.79% during the quarter. The current value of the position is $5,926,306 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-22 2026-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 13,263 104 0.79 5,922 -0.72 0.9662
2026-01-20 2025-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 13,159 -200 -1.50 5,966 14.03 0.9661
2025-10-09 2025-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 13,359 -1,666 -11.09 5,232 -21.80 0.8684
2025-07-30 2025-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,025 -186 -1.22 6,689 -9.29 1.2140
2025-04-11 2025-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,211 79 0.52 7,375 21.02 1.4641
2025-01-24 2024-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,132 -74 -0.49 6,094 -13.84 1.1395
2024-10-29 2024-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,206 122 0.81 7,072 0.03 1.3753
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,084 880 6.20 7,070 19.08 1.5603
2024-04-29 2024-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 14,204 -846 -5.62 5,937 -3.04 1.4125
2024-01-22 2023-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,050 255 1.72 6,124 19.03 1.5397
2023-10-27 2023-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 14,795 688 4.88 5,145 3.63 1.4602
2023-08-04 2023-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 14,107 -1,261 -8.21 4,964 2.54 1.4508
2023-04-20 2023-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,368 400 2.67 4,842 120,925.00 1.3936
2023-02-06 2022-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 14,968 -55 -0.37 4 -99.91 1.3994
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,023 40 0.27 4,350 3.03 1.5166
2022-08-04 2022-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 14,983 -219 -1.44 4,222 6.43 1.3642
2022-05-06 2022-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,202 -580 -3.68 3,967 14.45 1.1018
2022-02-02 2021-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 15,782 -1,058 -6.28 3,466 13.45 0.9704
2021-11-08 2021-09-30 13F/A-1 VERTEX PHARMACEUTICALS INC COM Stock 92532F100 16,840 283 1.71 3,055 -8.48 0.9311
2021-11-03 2021-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 3,055 -13,502 3,055 0.9311
2021-08-04 2021-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 16,557 -652 -3.79 3,338 -9.73 1.0168
2021-05-11 2021-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 17,209 4 0.02 3,698 -9.05 1.1962
2021-02-09 2020-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 17,205 -28 -0.16 4,066 -13.29 1.4232
2020-10-27 2020-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 17,233 258 1.52 4,689 -4.85 1.8923
2020-08-11 2020-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 16,975 255 1.53 4,928 23.85 1.5377
2020-04-28 2020-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 16,720 2,175 14.95 3,979 24.97 1.7621
2020-02-10 2019-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 14,545 1,150 8.59 3,184 41.83 1.2874
2019-12-03 2019-09-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 13,395 446 3.44 2,245 -5.47 1.2799
2019-09-06 2019-06-30 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 12,949 318 2.52 2,375 2.24 1.4260
2019-05-23 2019-03-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 12,631 -7,180 -36.24 2,323 -29.24 1.5909
2019-02-26 2018-12-31 13F VERTEX PHARMACEUTICALS INC COM Stock 92532F100 19,811 19,811 3,283 2.8951
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.